Navigate Fool.com
Will ACOR beat
the market?

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

Community Rating: 3 Stars: Appealing

29.51 -0.05 (-0.17%)

REAL-TIME: Last trade at

Extended Hours: $29.51 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $29.43
Previous Close $29.56
Daily Range $29.27 - $29.70
52-Week Range $27.51 - $39.95
Market Cap $1.2B
P/E Ratio 64.26
Dividend (Yield) $0.00 (0.0%)
Volume 228,922
Average Daily Volume 694,475
Current FY EPS $0.37

How do you think ACOR
will perform against the market?

Top ACOR Bull/Bear Pitches


zzlangerhans (< 20)
Submitted October 14, 2010

Acorda seems to be wandering in a sine wave pattern as alternatively optimistic and pessimistic views of the commercial potential of their multiple sclerosis drug Ampyra. Ampyra is far from a proven w … More

0 Replies Reply Report this Post

Hogty (< 20)
Submitted September 1, 2009

Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the … More

1 Replies Reply Report this Post

News & Commentary

Why AeroVironment, Acorda Therapeutics, and Chicago Bridge & Iron Tumbled Today

Even though the stock market managed to post modest gains, these stocks missed out. Find out why.

Markets Edge Higher; Alcoa Profit Beats Street View

Sector Update: Healthcare Shares Flat Pre-Market; Acorda Could File Patent Infringement Suit

Sector Update: Healthcare

ACOR Makes Notable Cross Below Critical Moving Average

Sector Update: Healthcare

Sector Update: Healthcare Shares Flat Pre-Market; Pfizer Teams with Cellectis on Immunotherapy

Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session

Why Acorda Therapeutics Inc. Shares Sank

Acorda shares take a tumble after announcing plans to take on debt. Find out whether this is short-term noise or something to really be concerned about.

Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble

See More ACOR News...





Acorda Therapeutics, Inc. (ACOR) Description

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS. Website: http://www.acorda.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks